Benjamin Wolfson
Overview
Explore the profile of Benjamin Wolfson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
795
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Franks S, Fabian K, Santiago-Sanchez G, Wolfson B, Hodge J
Oncoimmunology
. 2022 Oct;
11(1):2124666.
PMID: 36211806
Immune checkpoint blockade (ICB) therapy, while groundbreaking, must be improved to promote enhanced durable responses and to prevent the development of treatment-refractory disease. Cancer therapies that engage, enable, and expand...
2.
Fabian K, Wolfson B, Hodge J
Front Oncol
. 2021 Sep;
11:728018.
PMID: 34497771
Cancer treatment has rapidly entered the age of immunotherapy, and it is becoming clear that the effective therapy of established tumors necessitates rational multi-combination immunotherapy strategies. But even in the...
3.
Wolfson B, Padget M, Schlom J, Hodge J
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34244306
Background: There are highly effective treatment strategies for estrogen receptor (ER)+, progesterone receptor (PR)+, and HER2+ breast cancers; however, there are limited targeted therapeutic strategies for the 10%-15% of women...
4.
Wolfson B, Franks S, Hodge J
Vaccines (Basel)
. 2021 Jun;
9(5).
PMID: 34063388
Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. While these combinations build on the...
5.
Fabian K, Malamas A, Padget M, Solocinski K, Wolfson B, Fujii R, et al.
Cancer Immunol Res
. 2020 Dec;
9(2):239-252.
PMID: 33355290
Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To...
6.
Franks S, Wolfson B, Hodge J
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32751977
Cellular therapy has emerged as an attractive option for the treatment of cancer, and adoptive transfer of chimeric antigen receptor (CAR) expressing T cells has gained FDA approval in hematologic...
7.
Solocinski K, Padget M, Fabian K, Wolfson B, Cecchi F, Hembrough T, et al.
J Immunother Cancer
. 2020 Apr;
8(1).
PMID: 32345623
Background: Natural killer (NK) cells are immune cells capable of killing virally infected cells and tumor cells without the need for antigen stimulation. Tumors, however, can create a suppressive microenvironment...
8.
Fenerty K, Padget M, Wolfson B, Gameiro S, Su Z, Lee J, et al.
J Immunother Cancer
. 2019 Sep;
7(1):234.
PMID: 31477176
Following publication of the original article [1], an error was noted in the GAPDH in the western blot depicted in Figure 4b.
9.
Fenerty K, Padget M, Wolfson B, Gameiro S, Su Z, Lee J, et al.
J Immunother Cancer
. 2018 Nov;
6(1):133.
PMID: 30486888
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a...
10.
Wolfson B, Lo P, Yao Y, Li L, Wang H, Zhou Q
Mol Nutr Food Res
. 2018 Apr;
62(13):e1800189.
PMID: 29701903
Scope: We have previously shown that loss of miR-140 has a pro-fibrotic effect in the mammary gland. This study aims to investigate whether miR-140 loss and obesity act synergistically to...